(MYGN) Myriad Genetics - Ratings and Ratios
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US62855J1043
MYGN: Molecular, Diagnostic, Tests, Oncology, Genetics, Screening, Health
Myriad Genetics, Inc. (NASDAQ:MYGN) is a leader in molecular diagnostic testing and precision medicine, specializing in the development and commercialization of innovative diagnostic products. The company focuses on advancing personalized medicine through its portfolio of genetic tests designed to assess risks for hereditary cancers, guide cancer therapy selection, and provide insights into various health conditions. Myriads offerings include the MyRisk Hereditary Cancer test, which uses DNA sequencing to evaluate genetic cancer risks; BRACAnalysis CDx, a companion diagnostic test for metastatic cancers linked to BRCA variants; and MyChoice CDx, which identifies homologous recombination deficiency in ovarian cancer patients.
The company also provides Prolaris, a prostate cancer prognostic test analyzing RNA expression to determine disease aggressiveness, and EndoPredict, a breast cancer prognostic test using RNA expression to assess tumor biology. Myriads portfolio extends to prenatal and mental health testing, including the Prequel Prenatal Screen for chromosomal disorders, Foresight Carrier Screen for genetic risk assessment, SneakPeek for early gender prediction, and GeneSight for psychotropic medication selection in mental health conditions. Collaborations with Illumina, Memorial Sloan Kettering, MD Anderson, and Flatiron Health underscore its commitment to advancing precision medicine.
Founded in 1991 and headquartered in Salt Lake City, Utah, Myriad Genetics operates at the intersection of genomics and healthcare, aiming to improve patient outcomes through actionable genetic insights. Its diverse product lineup addresses critical areas in oncology, womens health, and pharmacogenomics, positioning it as a key player in the molecular diagnostics industry.
Additional Sources for MYGN Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
MYGN Stock Overview
Market Cap in USD | 697m |
Sector | Healthcare |
Industry | Diagnostics & Research |
GiC Sub-Industry | Biotechnology |
IPO / Inception | 1995-10-05 |
MYGN Stock Ratings
Growth Rating | -66.4 |
Fundamental | -20.7 |
Dividend Rating | 0.08 |
Rel. Strength | -80.8 |
Analysts | 3.33/5 |
Fair Price Momentum | 3.58 USD |
Fair Price DCF | - |
MYGN Dividends
Dividend Yield 12m | 0.00% |
Yield on Cost 5y | % |
Annual Growth 5y | 0.00% |
Payout Consistency | 0.3% |
MYGN Growth Ratios
Growth Correlation 3m | -97.4% |
Growth Correlation 12m | -85.2% |
Growth Correlation 5y | -20% |
CAGR 5y | -24.01% |
CAGR/Max DD 5y | -0.27 |
Sharpe Ratio 12m | -1.31 |
Alpha | -93.54 |
Beta | 0.957 |
Volatility | 174.83% |
Current Volume | 7304k |
Average Volume 20d | 2039.4k |
As of May 09, 2025, the stock is trading at USD 4.03 with a total of 7,304,023 shares traded.
Over the past week, the price has changed by -43.48%, over one month by -47.87%, over three months by -67.63% and over the past year by -83.17%.
Neither. Based on ValueRay Fundamental Analyses, Myriad Genetics is currently (May 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of -20.73 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of MYGN as of May 2025 is 3.58. This means that MYGN is currently overvalued and has a potential downside of -11.17%.
Myriad Genetics has received a consensus analysts rating of 3.33. Therefor, it is recommend to hold MYGN.
- Strong Buy: 3
- Buy: 3
- Hold: 6
- Sell: 2
- Strong Sell: 1
According to ValueRays Forecast Model, MYGN Myriad Genetics will be worth about 4 in May 2026. The stock is currently trading at 4.03. This means that the stock has a potential downside of -0.5%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 15.3 | 279.7% |
Analysts Target Price | 21.2 | 426.1% |
ValueRay Target Price | 4 | -0.5% |